Gossamer Bio’s (GOSS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Gossamer Bio (NASDAQ:GOSS) in a report released on Thursday morning,Benzinga reports. HC Wainwright currently has a $10.00 target price on the stock. HC Wainwright also issued estimates for Gossamer Bio’s FY2029 earnings at $0.59 EPS.

Gossamer Bio Trading Up 4.9 %

NASDAQ:GOSS opened at $0.96 on Thursday. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. The firm has a market cap of $218.37 million, a price-to-earnings ratio of -3.01 and a beta of 1.81. Gossamer Bio has a 52 week low of $0.50 and a 52 week high of $1.60. The firm has a 50-day moving average price of $0.86 and a two-hundred day moving average price of $0.90.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.04. The company had revenue of $9.48 million for the quarter, compared to analysts’ expectations of $4.52 million. On average, equities analysts expect that Gossamer Bio will post -0.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Gossamer Bio

Several large investors have recently modified their holdings of GOSS. Sequoia Financial Advisors LLC grew its stake in Gossamer Bio by 26.7% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company’s stock valued at $117,000 after buying an additional 25,000 shares in the last quarter. US Bancorp DE purchased a new position in Gossamer Bio in the 3rd quarter valued at approximately $39,000. GSA Capital Partners LLP purchased a new position in Gossamer Bio in the 3rd quarter valued at approximately $67,000. The Manufacturers Life Insurance Company grew its stake in Gossamer Bio by 24.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company’s stock valued at $380,000 after buying an additional 74,920 shares in the last quarter. Finally, Algert Global LLC purchased a new position in Gossamer Bio in the 2nd quarter valued at approximately $75,000. Hedge funds and other institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.